Statement: Less than 5% of cohort 1 of the primary trial had High blood sugar, 0% of the secondary trial patients were recorded as having High blood sugar.
Primary_evidence: Adverse Events 1:   Total: 6/22 (27.27%)   Thrombocytopenia  1/22 (4.55%)   leucocytopenia  1/22 (4.55%)   neutropenia  1/22 (4.55%)   papilledema  1/22 (4.55%)   Nausea  1/22 (4.55%)   hyperglycemia  1/22 (4.55%)
Secondary_evidence: Adverse Events 1:   Total: 24/101 (23.76%)   LYMPHADENOPATHY 0/101 (0.00%)   FEBRILE NEUTROPENIA 20/101 (0.00%)   ATRIAL FIBRILLATION 1/101 (0.99%)   ARRHYTHMIA 20/101 (0.00%)   CARDIAC FAILURE 22/101 (1.98%)   CARDIAC FAILURE CONGESTIVE 20/101 (0.00%)   CORONARY OSTIAL STENOSIS 20/101 (0.00%)   LACRIMAL DISORDER 0/101 (0.00%)   BLINDNESS 21/101 (0.99%)   GASTRIC ULCER 1/101 (0.99%)   NAUSEA 1/101 (0.99%) Adverse Events 2:   Total: 22/103 (21.36%)   LYMPHADENOPATHY 1/103 (0.97%)   FEBRILE NEUTROPENIA 21/103 (0.97%)   ATRIAL FIBRILLATION 1/103 (0.97%)   ARRHYTHMIA 21/103 (0.97%)   CARDIAC FAILURE 20/103 (0.00%)   CARDIAC FAILURE CONGESTIVE 21/103 (0.97%)   CORONARY OSTIAL STENOSIS 21/103 (0.97%)   LACRIMAL DISORDER 1/103 (0.97%)   BLINDNESS 20/103 (0.00%)   GASTRIC ULCER 0/103 (0.00%)   NAUSEA 0/103 (0.00%)